NZ228111A - Stabilisation of 13,14-dihydro-15-keto prostaglandin compositions using etherised cyclodextrins - Google Patents

Stabilisation of 13,14-dihydro-15-keto prostaglandin compositions using etherised cyclodextrins

Info

Publication number
NZ228111A
NZ228111A NZ228111A NZ22811189A NZ228111A NZ 228111 A NZ228111 A NZ 228111A NZ 228111 A NZ228111 A NZ 228111A NZ 22811189 A NZ22811189 A NZ 22811189A NZ 228111 A NZ228111 A NZ 228111A
Authority
NZ
New Zealand
Prior art keywords
dihydro
cyclodextrins
etherised
stabilisation
keto prostaglandin
Prior art date
Application number
NZ228111A
Other languages
English (en)
Inventor
Ueno Ryuji
Kuno Sachiko
Original Assignee
Ueno Seiyaku Oyo Kenkyujo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ueno Seiyaku Oyo Kenkyujo Kk filed Critical Ueno Seiyaku Oyo Kenkyujo Kk
Publication of NZ228111A publication Critical patent/NZ228111A/xx

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Furan Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ228111A 1988-02-26 1989-02-23 Stabilisation of 13,14-dihydro-15-keto prostaglandin compositions using etherised cyclodextrins NZ228111A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP63045622A JP2597629B2 (ja) 1988-02-26 1988-02-26 13,14−ジヒドロ−15−ケトプロスタグランジン類の安定化

Publications (1)

Publication Number Publication Date
NZ228111A true NZ228111A (en) 1991-02-26

Family

ID=12724473

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ228111A NZ228111A (en) 1988-02-26 1989-02-23 Stabilisation of 13,14-dihydro-15-keto prostaglandin compositions using etherised cyclodextrins

Country Status (13)

Country Link
EP (1) EP0330511B1 (en:Method)
JP (1) JP2597629B2 (en:Method)
KR (1) KR970005170B1 (en:Method)
AT (1) ATE79260T1 (en:Method)
AU (1) AU612791B2 (en:Method)
CA (1) CA1314483C (en:Method)
DE (1) DE68902401T2 (en:Method)
ES (1) ES2044087T3 (en:Method)
GB (1) GB2216004A (en:Method)
GR (1) GR3005933T3 (en:Method)
NZ (1) NZ228111A (en:Method)
OA (1) OA09236A (en:Method)
ZA (1) ZA891410B (en:Method)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003274735B2 (en) * 2002-10-23 2008-12-04 Sucampo Ag Prostaglandin compounds for the treatment of obesity

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5236907A (en) * 1988-10-01 1993-08-17 R-Tech Ueno Ltd. Ocular hypotensive agents
ES2052735T3 (es) * 1987-09-18 1994-07-16 R Tech Ueno Ltd Un metodo para producir un agente hipotensor ocular.
US6420422B1 (en) 1987-09-18 2002-07-16 Sucampo Pharmaceuticals, Inc. Ocular hypotensive agents
US5166178B1 (en) * 1987-09-18 1998-07-21 R Tech Ueno Ltd Ocular hypotensive agents
US5212200A (en) * 1987-09-18 1993-05-18 R-Tech Ueno, Ltd. Ocular hypotensive agents
US5565492A (en) * 1988-07-18 1996-10-15 Alcon Laboratories, Inc. Prostaglandin combinations in glaucoma therapy
EP0569046B1 (en) * 1988-09-06 2002-11-13 Pharmacia Aktiebolag Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5194429A (en) * 1988-10-01 1993-03-16 K.K. Ueno Seiyaku Oyo Kenkyujo Ocular hypotensive agents
ATE162074T1 (de) * 1988-10-01 1998-01-15 R Tech Ueno Ltd Oculare hypotensive mittel
US5234954A (en) * 1989-07-27 1993-08-10 K.K. Ueno Seiyaku Oyo Kenkyujo Treatment of hyperlipidemia with 15-keto-prostaglandin compounds
DE69019431T2 (de) * 1989-07-27 1995-09-14 Ueno Seiyaku Oyo Kenkyujo Kk Verwendung von 15-Keto-Prostansäure-Derivaten zur Herstellung eines Medikaments für die Verbesserung der Ausscheidung des Kaliumions.
DE69018903T2 (de) * 1989-08-09 1995-08-24 Ueno Seiyaku Oyo Kenkyujo Kk Verwendung von Prostansäurederivaten zur Herstellung von Arzneimitteln zur Verbesserung der Ausscheidung von Nichtprotein in die Därme.
CA2027814C (en) * 1989-10-20 1996-07-30 Ryuji Ueno Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds
US5254588A (en) * 1989-11-22 1993-10-19 Kabushikikaisha Ueno Seiyaku Oyo Kenkyujo Treatment of pulmonary dysfunction with 15-ketoprostaglandin compounds
CA2030344C (en) * 1989-11-22 2000-04-18 Ryuji Ueno Treatment of pulmonary dysfunction with 15-keto-prostaglandin compounds
CA2030346C (en) * 1989-11-22 2000-04-11 Ryuji Ueno Treatment of cardiac dysfunction with 15-keto-prostaglandin compounds
US5256696A (en) * 1989-11-22 1993-10-26 Kabushikikaisha Ueno Seiyaku Oyo Kenkyujo Treatment of cardiac dysfunction with 15-ketoprostaglandin compounds
CA2031469A1 (en) * 1989-12-28 1991-06-29 Larry A. Wheeler Use of inclusion complexes of prostaglandins with cyclodextrins in the treatment of ocular hypertension
TW249226B (en:Method) * 1990-04-04 1995-06-11 Aderk Ueno Kk
CA2046069C (en) * 1990-07-10 2002-04-09 Ryuji Ueno Treatment of inflammatory diseases with 15-keto-prostaglandin compounds
ES2093774T3 (es) * 1991-03-14 1997-01-01 R Tech Ueno Ltd Estimulacion de la curacion de heridas con un compuesto 15-cetoprostaglandina.
US5510383A (en) * 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
US6184250B1 (en) 1993-08-03 2001-02-06 Alcon Laboratories, Inc. Use of cloprostenol and fluprostenol analogues to treat glaucoma and ocular hypertension
US5807892A (en) * 1994-09-30 1998-09-15 Alcon Laboratories, Inc. Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
US5698733A (en) * 1994-09-30 1997-12-16 Alcon Laboratories, Inc. Use of 9-deoxy prostaglandin derivatives to treat glaucoma
US5631287A (en) * 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US6011062A (en) * 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
AU7672096A (en) 1995-06-07 1998-06-03 Alcon Laboratories, Inc. Conformationally rigid aryl- or heteroaryl prostaglandins for use in glaucoma therapy
US6096783A (en) * 1998-12-15 2000-08-01 Alcon Laboratories, Inc. Cyclobutane prostaglandin analogues as ocular hypotensive agents
US6211226B1 (en) 1998-12-17 2001-04-03 Alcon Laboratories, Inc. 11-Aza prostaglandins for the treatment of glaucoma and ocular hypertension
WO2005044276A1 (ja) * 2003-11-07 2005-05-19 Senju Pharmaceutical Co., Ltd. プロスタグランジン含有医薬組成物
EP1985298A1 (en) 2007-04-24 2008-10-29 Azad Pharma AG Ophtalmic oil-in-water emulsions containing prostaglandins

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5910525A (ja) * 1982-06-21 1984-01-20 Teisan Seiyaku Kk プロスタグランジンeの安定化組成物
JPH0819004B2 (ja) * 1986-12-26 1996-02-28 日清製粉株式会社 徐放性医薬製剤
CA1322749C (en) 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
CA1323364C (en) 1987-01-28 1993-10-19 Ryuzo Ueno Prostaglandins e and anti ulcer agents containing same
CA1324129C (en) 1987-04-30 1993-11-09 Ryuzo Ueno Prostaglandins of the f series
DE3869471D1 (de) 1987-05-15 1992-04-30 Ueno Seiyaku Oyo Kenkyujo Kk Fiebersteigende zusammensetzung.
ES2052735T3 (es) 1987-09-18 1994-07-16 R Tech Ueno Ltd Un metodo para producir un agente hipotensor ocular.

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003274735B2 (en) * 2002-10-23 2008-12-04 Sucampo Ag Prostaglandin compounds for the treatment of obesity
US8114911B2 (en) 2002-10-23 2012-02-14 Sucampo Ag Prostaglandin compounds for the treatment of obesity

Also Published As

Publication number Publication date
JP2597629B2 (ja) 1997-04-09
KR970005170B1 (en) 1997-04-14
KR890012654A (ko) 1989-09-18
DE68902401T2 (de) 1992-12-10
EP0330511A2 (en) 1989-08-30
GB8904232D0 (en) 1989-04-12
EP0330511B1 (en) 1992-08-12
JPH01221317A (ja) 1989-09-04
AU3029889A (en) 1989-08-31
GB2216004A (en) 1989-10-04
CA1314483C (en) 1993-03-16
AU612791B2 (en) 1991-07-18
ZA891410B (en) 1989-11-29
GR3005933T3 (en:Method) 1993-06-07
ES2044087T3 (es) 1994-01-01
EP0330511A3 (en) 1989-10-18
ATE79260T1 (de) 1992-08-15
DE68902401D1 (de) 1992-09-17
OA09236A (en) 1992-06-30

Similar Documents

Publication Publication Date Title
NZ228111A (en) Stabilisation of 13,14-dihydro-15-keto prostaglandin compositions using etherised cyclodextrins
GB2257359B (en) Cyclosporin compositions for oral administration
FR2696461B1 (fr) Nouveaux dérivés d'analogues du taxol, leur préparation et les compositions qui les contiennent.
ATE148630T1 (de) Stabilisierte derivate von vitamin d2 und d3 enthaltende pharmazeutische zusammensetzungen
ZW9392A1 (en) Oral presentation forms for acid-unstable active compounds
MY126305A (en) Antifungal compositions
TW427906B (en) Antifungal compositions
NZ232946A (en) Preparation of crystalline 17alpha-hydroxy-7alpha methyl-19-nor-17-pregn-5
IL104158A (en) 4, 13-dioxabicyclo £8.2.1| tridecenone compounds and pharmaceutical compositions containing them
GR3031687T3 (en) Hgh containing pharmaceutical compositions
NZ225950A (en) Calcium citrate malate in the molar ratio of 6:2:3; pharmaceutical compositions
IE811650L (en) Stabilized thieno-pyridine compositions
MY104979A (en) [ 5(6)(ih-azole-1-ylmethyl) benzimidazole] carbamates.
AU3645489A (en) Insecticidaln'-substituted-n-alkylcarbonyl-n'- acylhydrazines and n'-substituted-n-acyl-n'- alkylcarbonylhydrazines
IL105475A (en) PHARMACEUTICAL COMPOSITIONS CONTAINING 1a, 24(R) - DIHYDROXY-22(E)-DEHYDRO- VITAMIN D3 FOR TREATING OSTEOPOROSIS
AU6061986A (en) Continuous release peptide composition
NZ217778A (en) Antiinflammatory compositions containing piroxicam
EP0348664A3 (en) Pharmaceutical compositions containing monoacetoacetins for treating tumours
AU2403592A (en) 2-aza-2-desamino analogues of 5,8-dideazafolic acid
EP0131950A3 (en) Quickly resorbable preparation of sparingly soluble active substances
KR970701559A (ko) 펩타이드의 경구 투여를 위한 안정화된 조성물(stabilized composition for oral administration of peptides)

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
ASS Change of ownership

Owner name: SUCAMPO AG, CH

Free format text: OLD OWNER(S): KABUSHIKIKAISHA UENO SEIYAKU OYO KENKYUJO